Oppenheimer Asset Management Inc. Buys 4,925 Shares of HealthEquity, Inc. (NASDAQ:HQY)

by · The Cerbat Gem

Oppenheimer Asset Management Inc. lifted its position in HealthEquity, Inc. (NASDAQ:HQY – Free Report) by 7.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,139 shares of the company’s stock after purchasing an additional 4,925 shares during the quarter. Oppenheimer Asset Management Inc. owned about 0.08% of HealthEquity worth $5,659,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of HealthEquity by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock worth $715,783,000 after buying an additional 149,133 shares in the last quarter. Clearbridge Investments LLC grew its position in HealthEquity by 1.9% in the second quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company’s stock worth $204,915,000 after acquiring an additional 43,491 shares in the last quarter. Mackenzie Financial Corp increased its stake in HealthEquity by 16.0% during the second quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock worth $203,822,000 after acquiring an additional 325,906 shares during the last quarter. Dimensional Fund Advisors LP raised its position in HealthEquity by 8.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,547,402 shares of the company’s stock valued at $133,377,000 after purchasing an additional 115,841 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of HealthEquity by 0.8% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,122,057 shares of the company’s stock valued at $96,721,000 after purchasing an additional 9,125 shares during the last quarter. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HQY shares. JMP Securities reissued a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft increased their target price on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $92.00 price target on shares of HealthEquity in a research note on Wednesday, September 4th. Bank of America upped their price target on shares of HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday. Finally, BTIG Research raised their price objective on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $107.17.

Check Out Our Latest Research Report on HQY

HealthEquity Price Performance

NASDAQ HQY opened at $95.70 on Friday. The company has a market cap of $8.36 billion, a PE ratio of 79.75, a P/E/G ratio of 1.57 and a beta of 0.52. The firm’s 50 day moving average price is $84.56 and its 200-day moving average price is $80.94. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. HealthEquity, Inc. has a 52-week low of $62.10 and a 52-week high of $101.17.

HealthEquity (NASDAQ:HQY – Get Free Report) last announced its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.16. The business had revenue of $299.93 million for the quarter, compared to analysts’ expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. Sell-side analysts forecast that HealthEquity, Inc. will post 2.27 EPS for the current fiscal year.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Frank Corvino sold 1,039 shares of HealthEquity stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the transaction, the director now directly owns 3,784 shares of the company’s stock, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert W. Selander sold 8,250 shares of the firm’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the sale, the director now directly owns 54,719 shares of the company’s stock, valued at $4,540,582.62. The trade was a 13.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,536 shares of company stock worth $884,517 over the last quarter. Insiders own 2.20% of the company’s stock.

HealthEquity Company Profile

(Free Report)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Articles

Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY – Free Report).